MT3 and Alzheimer disease: Many studies show that MT‐3 mRNA is downregulated in AD brains (Barnham et al., 2004; Carrasco et al., 1999; Kim, Nam, Jeon, Han, & Suk, 2012; Naruse et al., 1994; Streit, 2004; Uchida, Takio, Titani, Ihara, & Tomonaga, 1991; Yu, Lukiw, Bergeron, Niznik, & Fraser, 2001); this might, therefore, contribute to the upsurge of abnormal neuronal development that is associated with the disease.